No data to show
XETR
APPH
Market cap104mUSD
May 16, Last price
11.20EUR
1D
-0.44%
1Q
2.75%
IPO
-39.46%
Name
Apontis Pharma AG
Chart & Performance
P/E
123.81
P/S
1.92
EPS
0.09
Div Yield, %
—
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
3.90%
Revenues
48m
+31.12%
Net income
754k
P
CFO
0k
P
Profile
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It develops, promotes, and sells a portfolio of single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prevention, as well as respiratory diseases and diabetes. The company was founded in 1946 is headquartered in Monheim am Rhein, Germany.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | |||||||
Revenues | 48,467 31.12% | 36,964 -33.67% | 55,727 8.87% | ||||
Cost of revenue | 26,267 | 20,205 | 25,802 | ||||
Unusual Expense (Income) | |||||||
NOPBT | 22,201 | 16,759 | 29,925 | ||||
NOPBT Margin | 45.81% | 45.34% | 53.70% | ||||
Operating Taxes | 400 | (3,543) | 1,139 | ||||
Tax Rate | 1.80% | 3.81% | |||||
NOPAT | 21,801 | 20,301 | 28,785 | ||||
Net income | 754 -106.67% | (11,303) -520.38% | 2,689 | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | (1,836) | ||||||
BB yield | 2.63% | ||||||
| Debt | |||||||
Debt current | 6,020 | ||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | 8,549 | 15,258 | 11,016 | ||||
Net debt | (15,455) | (21,597) | (37,579) | ||||
| Cash flow | |||||||
Cash from operating activities | (12,600) | 11,020 | |||||
CAPEX | (3,263) | ||||||
Cash from investing activities | (2,900) | ||||||
Cash from financing activities | 6,000 | ||||||
FCF | 22,539 | 16,910 | 33,758 | ||||
| Balance | |||||||
Cash | 15,455 | 26,816 | 36,345 | ||||
Long term investments | 801 | 1,234 | |||||
Excess cash | 13,031 | 25,769 | 34,792 | ||||
Stockholders' equity | 8,500 | 8,500 | 8,500 | ||||
Invested Capital | 31,066 | 43,041 | 43,480 | ||||
ROIC | 58.84% | 46.93% | 67.26% | ||||
ROCE | 56.03% | 32.00% | 56.16% | ||||
| EV | |||||||
Common stock shares outstanding | 8,496 | 8,500 | 8,500 | ||||
Price | 10.05 111.58% | 4.75 -42.07% | 8.20 -59.00% | ||||
Market cap | 85,382 111.47% | 40,375 -42.07% | 69,700 -59.00% | ||||
EV | 69,927 | 18,778 | 32,121 | ||||
EBITDA | 24,440 | 18,643 | 29,926 | ||||
EV/EBITDA | 2.86 | 1.01 | 1.07 | ||||
Interest | 170 | 71 | 48 | ||||
Interest/NOPBT | 0.77% | 0.42% | 0.16% | ||||